Trial Outcomes & Findings for T-DOC® 5 Fr Pediatric Clinical Investigation (NCT NCT03429270)

NCT ID: NCT03429270

Last Updated: 2020-06-09

Results Overview

A binary clinician response after each UDS study is used to assess if it is clinically adequate (success) or inadequate (failure) in each patients questionnaire and presented to the clinician where safety (Yes the device is safe and No the device is not safe) will be reported. A minimum of 10 male and 10 female subjects, with an overall minimum of 28, and maximum of 33 subjects.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

28 participants

Primary outcome timeframe

2 months

Results posted on

2020-06-09

Participant Flow

Participant milestones

Participant milestones
Measure
Urodynamics Arm
Urodynamic testing and data collection(per protocol) using the TDOC 5Fr catheters.
Overall Study
STARTED
28
Overall Study
COMPLETED
28
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Urodynamics Arm
n=28 Participants
TDOC 5Fr: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
Age, Categorical
<=18 years
28 Participants
n=28 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=28 Participants
Age, Categorical
>=65 years
0 Participants
n=28 Participants
Sex: Female, Male
Female
10 Participants
n=28 Participants
Sex: Female, Male
Male
18 Participants
n=28 Participants

PRIMARY outcome

Timeframe: 2 months

A binary clinician response after each UDS study is used to assess if it is clinically adequate (success) or inadequate (failure) in each patients questionnaire and presented to the clinician where safety (Yes the device is safe and No the device is not safe) will be reported. A minimum of 10 male and 10 female subjects, with an overall minimum of 28, and maximum of 33 subjects.

Outcome measures

Outcome measures
Measure
Urodynamics Arm
n=28 Participants
TDOC 5Fr: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
The Number of Patients in Which the T-DOC® 5 Fr Catheters Are Safe in Measuring Urodynamic Pressures in Pediatric Subjects (12 Years of Age and Younger).
28 Participants

PRIMARY outcome

Timeframe: 2 months

A binary clinician response after each UDS study is used to assess if it is clinically adequate (success) or inadequate (failure) in each patients questionnaire and presented to the clinician where effectiveness (Yes the device is effective and No the device is not effective) will be reported. A minimum of 10 male and 10 female subjects, with an overall minimum of 28, and maximum of 33 subjects.

Outcome measures

Outcome measures
Measure
Urodynamics Arm
n=28 Participants
TDOC 5Fr: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
The Number of Patients in Which the T-DOC® 5 Fr Catheters Are Effective in Measuring Urodynamic Pressures in Pediatric Subjects (12 Years of Age and Younger).
28 Participants

Adverse Events

Urodynamics Arm

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Urodynamics Arm
n=28 participants at risk
TDOC 5Fr: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
Renal and urinary disorders
Dysuria
10.7%
3/28 • Number of events 3 • Through study completion, an average of 5 to 7 days
Gastrointestinal disorders
Hematochezia
3.6%
1/28 • Number of events 1 • Through study completion, an average of 5 to 7 days

Additional Information

Stephanie Gallone, Clinical Research Manager

Laborie

Phone: 9056121170

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60